This funding opportunity supports research to develop novel screening approaches and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening. It also targets high priority genetic conditions where screening may soon be possible. The focus is on improving screening accuracy and demonstrating the benefits of early treatment to support inclusion on newborn screening panels.
Eligible applicants include a wide range of U.S. institutions such as public and private higher education institutions, small businesses, nonprofits, government entities, and tribal organizations. Eligibility is broad and includes both for-profit and nonprofit organizations.
